These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 12410584)

  • 1. Effect of ABO blood group on the collagen-binding assay for von Willebrand factor.
    Haley E; Babar N; Ritter C; Downes KA; Green D; Shurin S; Sarode R
    Am J Hematol; 2002 Nov; 71(3):229-31. PubMed ID: 12410584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Von Willebrand factor collagen-binding (activity) assay in the diagnosis of von Willebrand disease: a 15-year journey.
    Favaloro EJ
    Semin Thromb Hemost; 2002 Apr; 28(2):191-202. PubMed ID: 11992242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of von Willebrand disorder and identification of qualitative von Willebrand factor defects. Direct comparison of commercial ELISA-based von Willebrand factor activity options.
    Favaloro EJ
    Am J Clin Pathol; 2000 Oct; 114(4):608-18. PubMed ID: 11026108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discrimination of von Willebrands disease (VWD) subtypes: direct comparison of von Willebrand factor:collagen binding assay (VWF:CBA) with monoclonal antibody (MAB) based VWF-capture systems.
    Favaloro EJ; Henniker A; Facey D; Hertzberg M
    Thromb Haemost; 2000 Oct; 84(4):541-7. PubMed ID: 11057847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of ABO(H) and I blood group system development with von Willebrand factor and Factor VIII plasma levels in children and adolescents.
    Klarmann D; Eggert C; Geisen C; Becker S; Seifried E; Klingebiel T; Kreuz W
    Transfusion; 2010 Jul; 50(7):1571-80. PubMed ID: 20210927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Reliable von Willebrand factor: ristocetin cofactor enzyme-linked immunosorbent assay to differentiate between type 1 and type 2 von Willebrand disease.
    Vanhoorelbeke K; Cauwenberghs N; Vandecasteele G; Vauterin S; Deckmyn H
    Semin Thromb Hemost; 2002 Apr; 28(2):161-6. PubMed ID: 11992239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor.
    Turecek PL; Siekmann J; Schwarz HP
    Semin Thromb Hemost; 2002 Apr; 28(2):149-60. PubMed ID: 11992238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis.
    Favaloro EJ; Soltani S; McDonald J; Grezchnik E; Easton L; Favaloro JW
    Am J Clin Pathol; 2005 Dec; 124(6):910-7. PubMed ID: 16416741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source.
    Favaloro EJ
    Thromb Haemost; 2000 Jan; 83(1):127-35. PubMed ID: 10669166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Application of collagen-binding assay for von Willebrand disease].
    Zhou J; Jia YQ; Jiang H; Yang YM; Deng CQ
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jan; 35(1):126-9. PubMed ID: 14981837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two von Willebrand factor collagen-binding assays with different binding affinities for low, medium, and high multimers of von Willebrand factor.
    Neugebauer BM; Goy C; Budek I; Seitz R
    Semin Thromb Hemost; 2002 Apr; 28(2):139-48. PubMed ID: 11992237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van Vliet HH
    Acta Haematol; 2009; 121(2-3):85-97. PubMed ID: 19506353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a collagen-binding activity assay as a screening test for type II von Willebrand disease in dogs.
    Sabino EP; Erb HN; Catalfamo JL
    Am J Vet Res; 2006 Feb; 67(2):242-9. PubMed ID: 16454628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Von Willebrand factor (vWF) antigen levels and function in healthy Thais.
    Rojnuckarin P; Akkawat B; Intragumtornchai T
    Southeast Asian J Trop Med Public Health; 2005 Sep; 36(5):1292-7. PubMed ID: 16438160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution of von Willebrand factor levels in young women with and without bleeding symptoms: influence of ABO blood group and promoter haplotypes.
    Lethagen S; Hillarp A; Ekholm C; Mattson E; Halldén C; Friberg B
    Thromb Haemost; 2008 Jun; 99(6):1013-8. PubMed ID: 18521502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cold storage of citrated whole blood induces drastic time-dependent losses in factor VIII and von Willebrand factor: potential for misdiagnosis of haemophilia and von Willebrand disease.
    Böhm M; Täschner S; Kretzschmar E; Gerlach R; Favaloro EJ; Scharrer I
    Blood Coagul Fibrinolysis; 2006 Jan; 17(1):39-45. PubMed ID: 16607078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma derived von Willebrand factor preparations: collagen binding and ristocetin cofactor activities.
    Chang P; Aronson DL
    Thromb Haemost; 1997 Aug; 78(2):930-3. PubMed ID: 9268197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
    Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.